Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were also impressed by the tolerability profile.

Scroll to Top